

AusBiotech recognizes bioscience innovators

04 November 2014 | News | By BioSpectrum Bureau



Singapore: Australia has acknowledged its bioscience innovators and companies through an industry excellence awards organized by AusBiotech, country's biotech association.

Dr Chris Nave, managing director, Brandon Capital Partner was recognised for his leadership role in commercialising early stage medical research technology in Australia and for his mentoring of a number of young executives. In particular he drove the formation of The Medical Research Commercialisation Fund (MRCF) Collaboration in 2007 as an innovative collaborative approach to investing in early stage development and commercialisation opportunities emanating from Australian medical research institutes and allied research hospitals.

Atomo was named Emerging Company of the Year for its award-winning development of a next-generation rapid diagnostic platform that replaces ineffectual 'bits in a box test kits' with an integrated, all-in-one test ideal for the self-testing - thereby expanding the application.

Uscom was awarded Company of the Year for its work developing medical devices that specialise in the design and manufacture of non-invasive cardiac monitoring equipment.

Mr Dong Wu, Head of Johnson & Johnson Innovation Asia Pacific, said, "These award recipients are aiming to improve the health of people across the globe, which is a very noble mission and we are delighted to sponsor these awards that help recognise this important work."

Dr Anna Lavelle, chief executive officer, AusBiotech mentioned that each winner has made a significant contribution to the sector, and to the ongoing growth of Australia's biotechnology and medical technology.

"These awards recognise the standard-bearers for excellence in our industry," Dr Lavelle said. "They also point to what can be achieved when innovation is accompanied by the business acumen needed to bring novel medicines, medical devices and other new technologies to key markets."